Mostrar el registro sencillo del ítem

dc.contributor.authorCalle Rubio, Myriam
dc.contributor.authorCasas Maldonado, Francisco 
dc.date.accessioned2023-03-13T08:09:19Z
dc.date.available2023-03-13T08:09:19Z
dc.date.issued2023-01-30
dc.identifier.citationCalle Rubio, M... [et al.]. COVID-19’s impact on care practice for alpha-1-antitrypsin deficiency patients. BMC Health Serv Res 23, 98 (2023). [https://doi.org/10.1186/s12913-023-09094-3]es_ES
dc.identifier.urihttps://hdl.handle.net/10481/80545
dc.description.abstractBackground Patients with alpha-1 antitrypsin deficiency (AATD), commonly categorized as a rare disease, have been affected by the changes in healthcare management brought about by COVID-19. This study’s aim was to identify the changes that have taken place in AATD patient care as a result of the COVID-19 pandemic in Spain and to propose experts’ recommendations aimed at ensuring humanized and quality care for people with AATD in the post-pandemic situation. Methods A qualitative descriptive case study with a holistic single-case design was conducted, using focus groups with experts in AATD clinical management, including 15 health professionals with ties to the Spanish health system (12 pneumologists and 2 hospital pharmacists from 11 different hospitals in Spain) and 1 patient representative. Results COVID-19 has had a major impact on numerous aspects of AATD clinical patient management in Spain, including diagnostic, treatment, and follow-up phases. The experts concluded that there is a need to strengthen coordination between Primary Care and Hospital Care and improve the coordination processes across all the organizations and actors involved in the healthcare system. Regarding telemedicine and telecare, experts have concluded that it is necessary to promote this methodology and to develop protocols and training programs. Experts have recommended developing personalized and precision medicine, and patient participation in decision-making, promoting self-care and patient autonomy to optimize their healthcare and improve their quality of life. The possibility of monitoring and treating AATD patients from home has also been proposed by experts. Another result of the study was the recommendation of the need to ensure that plasma donations are made on a regular basis by a sufficient number of healthy individuals. Conclusion The study advances knowledge by highlighting the challenges faced by health professionals and changes in AATD patient management in the context of the COVID-19 pandemic. It also proposes experts’ recommendations aimed at ensuring humanized and quality care for people with AATD in the post-pandemic situation. This work could serve as a reference study for physicians on their daily clinical practice with AATD patients and may also provide guidance on the changes to be put in place for the post-pandemic situation.es_ES
dc.description.sponsorshipCSL Behringes_ES
dc.language.isoenges_ES
dc.publisherBMCes_ES
dc.rightsAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectCOVID-19es_ES
dc.subjectAlpha-1-antitrypsin deficiencyes_ES
dc.subjectRecommendationses_ES
dc.subjectPatient managementes_ES
dc.subjectHealthcare systemes_ES
dc.subjectRare diseasees_ES
dc.subjectDiagnostices_ES
dc.subjectTreatment es_ES
dc.subjectFollow-upes_ES
dc.subjectAATDes_ES
dc.titleCOVID‑19’s impact on care practice for alpha‑1‑antitrypsin deficiency patientses_ES
dc.typejournal articlees_ES
dc.rights.accessRightsopen accesses_ES
dc.identifier.doi10.1186/s12913-023-09094-3
dc.type.hasVersionVoRes_ES


Ficheros en el ítem

[PDF]

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución 4.0 Internacional